Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 5/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18202978 | 0.80 | ALOX15 (0.64) | ALOX15TSHRCYP3A4CYP2D6USP2 | |
| SCHEMBL952226 | 0.79 | ALOX15 (0.55) | ALOX15TSHRCYP3A4CYP2D6USP2 | |
| SCHEMBL4487346 | 0.77 | ALOX15 (0.59) | ALOX15TSHRCYP3A4CYP2D6USP2 | |
| SCHEMBL16812421 | 0.76 | ALOX15 (0.59) | ALOX15TSHRCYP3A4CYP2D6USP2 | |
| SCHEMBL807362 | 0.75 | ALOX15 (0.58) | ALOX15TSHRCYP3A4CYP2D6USP2 | |
| SCHEMBL18199692 | 0.75 | ALOX15 (0.58) | ALOX15TSHRCYP3A4CYP2D6USP2 | |
| SCHEMBL18506828 | 0.75 | ALOX15 (0.58) | ALOX15TSHRCYP3A4CYP2D6USP2 | |
| SCHEMBL6482630 | 0.74 | ALOX15 (0.56) | ALOX15TSHRCYP3A4CYP2D6USP2 | |
| SCHEMBL14338850 | 0.74 | ALOX15 (0.56) | ALOX15TSHRCYP3A4CYP2D6USP2 | |
| SCHEMBL1958015 | 0.73 | ALOX15 (0.52) | ALOX15TSHRCYP3A4CYP2D6USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245552-A1 | N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis | GLAXO GROUP LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
| EP-1492533-A1 | N-SUBSTITUTED PYRIDINONE AND PYRIMIDINONE DERIVATIVES FOR USE AS LP-PLA2 INHIBITORS IN THE TREATMENT OF ARTHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003086400-A1 | N-SUBSTITUTED PYRIDINONE AND PYRIMIDINONE DERIVATIVES FOR USE AS LP-PLA2 INHIBITORS IN THE TREATMENT OF ARTHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245552-A1 | N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis | PLA2G12A, PLA2G4B, PLA2G1B | ALOX15 50/4885TSHR 4247/4885CYP3A4 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.